Currently, molecular markers used for identifying and classifying gliomas, including isocitrate dehydrogenase 1 (IDH1) mutation, O6-methylguanylmethyltransferase (MGMT) promoter methylation, 1p/19q chromosome deletion and p53 mutation, have also been shown to have prognostic value for patients with DLGGs (11–16). This evidence concerns the gene IDH1 and central nervous system cancer.